Study highlights racial and ethnic disparities in disability among older adults

BMS updated its 2023 guidance, with the total revenues now expected to see a low single-digit reduction. Credit: Tada Images / Shutterstock.com. Bristol Myers Squibb

Mer­ck’s block­buster can­cer drug Keytru­da made $18.4 bil­lion in the first nine months of the year — near­ly the same amount as the re­port­ed rev­enue

Leo Phar­ma plans to ac­quire der­ma­tol­ogy biotech Tim­ber Phar­ma­ceu­ti­cals, which is de­vel­op­ing a treat­ment for a rare, ge­net­ic skin dis­ease. The pri­vate­ly held Dan­ish bio­phar­ma